Literature DB >> 10534148

Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS).

M Dorrucci1, M Balducci, P Pezzotti, A Sinicco, F Alberici, G Rezza.   

Abstract

OBJECTIVE: To evaluate changes in survival among HIV-positive individuals with known date of seroconversion (SC).
DESIGN: Prospective cohort study.
METHODS: Follow-up lasted from SC to death or to the end of 1997. A multivariate Cox model was applied to estimate relative hazards (RH) of death. The year of SC (as a categoric fixed variable) and calendar year (as a time-dependent variable) were considered to evaluate, respectively, cohort and prevalent changes in the rate of death. A separate Cox model was used to assess the association between survival and new combination therapies, using an "intention to treat" approach.
RESULTS: The study included 1535 individuals (53.9% injecting drug users, 25.3% homosexuals, 19.5% heterosexuals); 75.8% seroconverted between 1980 and 1991, and 24.2% seroconverted between 1992 and 1997. When adjusting for year of SC, the RH of death (and that of AIDS) was significantly lower in 1997, compared with before 1991 (RH = 0.54; 95% confidence interval, 0.30-0.98). Adjusted RHs of death were significantly lower for combination antiretroviral therapy, compared with no therapy. When combining the two Cox models, the 1997 reduction in risk of death was largely due to antiretroviral therapies; similar results were obtained when the endpoint was AIDS.
CONCLUSIONS: A reduction in the risk of death, probably due to combination antiretroviral therapy, was observed in 1997 after having adjusted for age at SC and year of SC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534148     DOI: 10.1097/00042560-199909010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

Authors:  Manuela García de la Hera; Inmaculada Ferreros; Julia del Amo; Patricia García de Olalla; Santiago Pérez Hoyos; Roberto Muga; Jorge del Romero; Rafael Guerrero; Ildefonso Hernández-Aguado
Journal:  J Epidemiol Community Health       Date:  2004-11       Impact factor: 3.710

3.  A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men.

Authors:  Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson
Journal:  J Clin Epidemiol       Date:  2009-10-31       Impact factor: 6.437

4.  Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.

Authors:  Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

5.  Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable.

Authors:  Lauren E Cain; Stephen R Cole; Sander Greenland; Todd T Brown; Joan S Chmiel; Lawrence Kingsley; Roger Detels
Journal:  Am J Epidemiol       Date:  2009-03-24       Impact factor: 4.897

6.  Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.

Authors:  J del Amo; J del Romero; A Barrasa; S Pérez-Hoyos; C Rodríguez; M Díez; S García; V Soriano; J Castilla
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

7.  Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

Authors:  Abdel Babiker; Janet Darbyshire; Patrizio Pezzotti; Kholoud Porter; Giovanni Rezza; Sarah A Walker; Valerie Beral; Roel Coutinho; Julia Del Amo; Noël Gill; Christine Lee; Laurence Meyer; Freya Tyrer; Francois Dabis; Rodolphe Thiebaut; Sylvie Lawson-Aye; Faroudy Boufassa; Osamah Hamouda; Klaus Fischer; Patrizio Pezzotti; Giovanni Rezza; Giota Touloumi; Angelos Hatzakis; Anastasia Karafoulidou; Olga Katsarou; Ray Brettle; Jorge del Romero; Maria Prins; Birgit van Benthem; Ole Kirk; Court Pederson; Idelfonso Hernández Aguado; Santiago Pérez-Hoyos; Anne Eskild; Johan N Bruun; Mette Sannes; Caroline Sabin; Christine Lee; Anne M Johnson; Andrew N Phillips; Patrick Francioli; Philippe Vanhems; Mathias Egger; Martin Rickenbach; David Cooper; John Kaldor; Lesley Ashton; Jeanette Vizzard; Roberto Muga; Nicholas E Day; Daniela De Angelis
Journal:  Int J Epidemiol       Date:  2002-10       Impact factor: 7.196

8.  Increasing risk behaviour can outweigh the benefits of antiretroviral drug treatment on the HIV incidence among men-having-sex-with-men in Amsterdam.

Authors:  Shan Mei; Rick Quax; David van de Vijver; Yifan Zhu; P M A Sloot
Journal:  BMC Infect Dis       Date:  2011-05-11       Impact factor: 3.090

9.  Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.

Authors:  Elena Raffetti; Laura Albini; Daria Gotti; Daniela Segala; Franco Maggiolo; Elisa di Filippo; Annalisa Saracino; Nicoletta Ladisa; Giuseppe Lapadula; Chiara Fornabaio; Filippo Castelnuovo; Salvatore Casari; Massimiliano Fabbiani; Piera Pierotti; Francesco Donato; Eugenia Quiros-Roldan
Journal:  BMC Public Health       Date:  2015-03-12       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.